STAMPEDE
STAMPEDE is the longest-running platform trial in oncology, and showed that both docetaxel and abiraterone extend life when started at first diagnosis of metastatic disease.
12,000+ men since 2005. Docetaxel arm (2016) and abiraterone arm (2017, OS HR 0.63) changed mHSPC treatment; prostate radiotherapy improves survival in low-volume metastatic disease (2018); abiraterone + enzalutamide adds toxicity without benefit; abiraterone in high-risk non-metastatic disease (2022).
- The treated group had about 40 percent lower chance of the event at any given time (hazard ratio 0.6).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- 6-year OS 60% 6-year OS 45%
- Median 60 vs 45 months with ADT + docetaxel compared with ADT alone; about 15 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 24 percent lower chance of the event at any given time (hazard ratio 0.76).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Multi-arm multi-stage platform in hormone-naive advanced prostate cancer: docetaxel, abiraterone, radiotherapy to the prostate, and more added to ADT. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
11,992 participants enrolled.
6-year OS 60% · 6-year OS 45%
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival, abiraterone arm (M1 subgroup)primary | ADT + abiraterone | — | 6-year OS 60% | 0.6 (0.5–0.71) | — | link |
| ADT alone | — | 6-year OS 45% | ||||
| Overall survival, docetaxel arm (M1) | ADT + docetaxel | — | 60 months | 0.76 | — | link |
| ADT alone | — | 45 months |
Pages like this
not linked directly; found by shared links- Key paperSTAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer
Shares Nicholas James, The Institute of Cancer Research, The Royal Marsden, Basket, umbrella, and platform trials.
- IdeaA standing platform trial for every major cancer, funded as infrastructure
Shares Basket, umbrella, and platform trials, Too many combinations to test, Trial design, endpoints and cost, Prostate cancer.
- TrialLATITUDE
Shares mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer), Abiraterone acetate, Prostate cancer.
- TrialPEACE-1
Shares Docetaxel, Abiraterone acetate, Prostate cancer.
- IdeaA non-profit phase 1b combination unit that any drug owner can use
Shares The Institute of Cancer Research, The Royal Marsden, Too many combinations to test.
- PersonJohann de Bono
Shares Abiraterone acetate, The Institute of Cancer Research, The Royal Marsden, Prostate cancer.
- IdeaLet the trial learn: response-adaptive allocation across many combination arms
Shares Basket, umbrella, and platform trials, Too many combinations to test, Trial design, endpoints and cost.
- IdeaFactorial trials that test several cheap generics at once in the adjuvant setting
Shares A perpetual platform trial in every major cancer, funded as infrastructure, Too many combinations to test.